Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00866749 · ClinicalTrials.gov registry record · Phase 2
Augmented Berlin-Frankfurt-Munster (BFM) Therapy for Adolescent/Young Adults With Acute Lymphoblastic Leukemia or Acute Lymphoblastic Lymphoma
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 120
- Enrollment target
NCT00866749: Completed Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT00866749 is a Phase 2 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 120 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00866749, a Phase 2 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 120 participants
- Enrollment target
Study Summary
Objectives: A. Primary objective: 1 To assess the feasibility and the effectiveness of pediatric type therapy (augmented BFM) in patients age 12 through 40 with untreated precursor-B or T acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LL). B. Secondary objective: 1. To evaluate the prognostic significance of minimal residual disease in bone marrow samples at the end of induction and at the end of consolidation in this group of patients. 2. To prospectively evaluate gene hypermethylation status in this group of patients. 3. To prospectively analyze asparaginase activity and anti-asparaginase antibody formation in this population of patients.
Interventions
- DRUG Cyclophosphamide
- DRUG Vincristine
- DRUG Daunorubicin
- DRUG PEG-asparaginase
- DRUG Intrathecal Methotrexate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2006-09-12 |
| Est. Completion | 2018-07-26 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00866749
The ClinicalTrials.gov registry entry for NCT00866749 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT00866749 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00866749 about?
NCT00866749 is a clinical study titled "Augmented Berlin-Frankfurt-Munster (BFM) Therapy for Adolescent/Young Adults With Acute Lymphoblastic Leukemia or Acute Lymphoblastic Lymphoma". Objectives: A. Primary objective: 1 To assess the feasibility and the effectiveness of pediatric type therapy (augmented BFM) in patients age 12 through 40 with untreated precursor-B or T acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LL). B. Secondary objective: 1. To evaluate th...
What is the current status of trial NCT00866749?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 120 participants. The study started on 2006-09-12. Estimated completion is 2018-07-26.
What interventions are being tested in trial NCT00866749?
The interventions under investigation include: Cyclophosphamide (DRUG), Vincristine (DRUG), Daunorubicin (DRUG), PEG-asparaginase (DRUG), Intrathecal Methotrexate (DRUG).
Who is sponsoring clinical trial NCT00866749?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.